The Public-Interest Patent Option
On July 29th, 2011, the U.S. federal appeals court reaffirmed, in effect, the right to patent genes, if in limited cases. The court’s ruling overturned a lower court decision that voided a patent held by Myriad Genetics on BRCA1 and BRCA2, two human genes used in determining the risk that women face with breast and ovarian cancer. Much hinges on the outcome of such patent challenges, given the thousands of genes that have been patented in the United States and elsewhere.
The appeals court accepted that the chemical structure of DNA, once removed from a cell was “markedly different” from . . . [more]


